IMUNON shares are trading higher after the company announced topline results from its Phase 2 OVATION 2 study with IMNN-001. The results showed an 11.1-month improvement in median overall survival compared to standard-of-care alone in the intent-to-treat population.
Portfolio Pulse from Benzinga Newsdesk
IMUNON shares are trading higher following the announcement of positive topline results from its Phase 2 OVATION 2 study with IMNN-001, showing an 11.1-month improvement in median overall survival compared to standard-of-care alone.
July 30, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IMUNON shares are trading higher after the company announced positive topline results from its Phase 2 OVATION 2 study with IMNN-001, showing an 11.1-month improvement in median overall survival compared to standard-of-care alone.
The significant improvement in median overall survival is a strong positive indicator for the efficacy of IMNN-001, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100